Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Female Pelvic Med Reconstr Surg. 2021 Jun 1;27(6):393–397. doi: 10.1097/SPV.0000000000000895

TABLE 4.

Sensitivity Analysis of Results of Final Model by Varying the Size Criterion for Defining Macrohematoma

Macrohematoma
Present
 Macrohematoma
Present
 Macrohematoma
Present
 OR (95% CI)
Adjusted for Oxytocin Use, Duration of
Second-Stage Labor, and BMI
Outcome Total (N = 90) Vaginal-Primiparous
(n = 46)		 Vaginal-Multiparous
(n = 44)		 *n = 84
Macrohematoma, ≥750 mm3 29 (32%) 20 (43%) 9 (20%) 1.83 (0.61–5.47)
Macrohematoma, ≥1000 mm3 23 (26%) 18 (39%) 5 (11%) 2.93 (0.78–10.91)
Macrohematoma, ≥1500 mm3 14 (16%) 12 (26%) 2 (5%) 6.02 (1.09–33.24)
Macrohematoma, ≥2000 mm3 10 (11%) 9 (20%) 1 (2%) 6.94 (0.75–64.63)
*

Second-stage labor information missing for 6 participants (n = 84).